Market Place
Sourcing Support
OncXerna doses first subject to evaluate navicixizumab in Phase II trial
09 Sep 2022 //
CLINICALTRIALSARENA
OncXerna Therapeutics Doses First Patient in Ph2 Trial Evaluating Navicixizumab
08 Sep 2022 //
GLOBENEWSWIRE
OncXerna Announces New Biomarker Data from Retrospective Analysis of Results
23 Oct 2021 //
GLOBENEWSWIRE
Oncologie Announces Key Updates and Planned Activities for its Clinical Programs
16 Jun 2020 //
PRNEWSWIRE
Mereo BioPharma & Oncologie Global Licensing Agreement for Navicixizumab
12 Feb 2020 //
GLOBENEWSWIRE
Oncologie Receives Exclusive Navicixizumab License
14 Jan 2020 //
CONTRACT PHARMA
Mereo & Oncologie Enter into Global Licensing Agreement for Navicixizumab
13 Jan 2020 //
PR NEWSWIRE
Mereo BioPharma Receives FDA Fast Track Designation for Navicixizumab
07 Oct 2019 //
YAHOO
Mereo BioPharma Group Merger Update: Acquisition of OncoMed
18 Apr 2019 //
GLOBENEWSWIRE
OncoMed Pharmaceuticals Announces Bayer Terminates
17 Jul 2017 //
GLOBENEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.